Aurobindo Pharma Usa., Inc, Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Aurobindo Pharma Usa., Inc, Pharmaceutical Import Records from India — 27 Products, $63.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aurobindo Pharma Usa., Inc, — Pharmaceutical Importer Profile (2026) | 27 Products, $63.1M Trade | TransData Nexus

Aurobindo Pharma Usa., Inc,

Pharmaceutical Importer · United States · Antibiotics Focus · $63.1M Total Trade · DGFT Verified

Aurobindo Pharma Usa., Inc, is a pharmaceutical importer based in United States with a total trade value of $63.1M across 27 products in 11 therapeutic categories. Based on 1,382 verified import shipments from Indian Customs (DGFT) records, Aurobindo Pharma Usa., Inc, is the #1 buyer in 2 products including Tamoxifen, Vati. Aurobindo Pharma Usa., Inc, sources from 2 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 99.6% of imports.

Aurobindo Pharma Usa., Inc, — Import Portfolio & Supplier Network

Aurobindo Pharma Usa., Inc, import network — 27 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Aurobindo Pharma Usa., Inc,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$11.3M	335	99.6%
Eugia Pharma Specialities Limited	$50.0K	1	0.4%

Aurobindo Pharma Usa., Inc, sources from 2 verified Indian suppliers across .

What Formulations Does Aurobindo Pharma Usa., Inc, Import?

Formulation	Value	Ships
Cefdinir capsules 300MG (cefdinir capsules USP 300MG	$1.0M	24
Amoxicillin and clavulanate potassium	$851.5K	28
Cefdinir oral suspension 250MG/5ML (cefdinir for oral suspension USP 250 MG/5 ML	$780.9K	20
Cefdinir oral suspension 250MG/5ML (cefdinir for oral suspension USP 250 MG/5 ML)	$591.1K	12
Amoxicillin for oral suspension	$550.4K	24
Cefdinir oral suspension 250MG/5ML (cefdinir for oral suspension USP 250MG/5 ML	$503.7K	11
Cefdinir capsules 300MG (cefdinir capsules USP 300 MG	$450.0K	9
Cefdinir capsules 300MG (cefdinir capsules USP 300 MG)	$402.7K	10
Cefdinir capsules 300MG (cefdinir capsules USP 300MG)	$400.0K	8
Cefpodoxime proxetil tablets 200MG (cefpodoxime proxetil tablets USP 200MG)	$350.0K	7
Cefdinir oral suspension 250MG/5ML (cefdinir for oral suspension USP 250MG/5 ML)	$325.3K	7
Amoxicillin capsules 500MG (amoxicillincapsules USP 500 MG)	$240.2K	6
Cefdinir oral suspension 250MG/5ML	$237.4K	7
Cefuroxime axetil tablets 500MG (cefuroxime axetil tablets 500 MG)	$214.8K	6
Cefdinir oral suspension 250MG/5ML (cefdinir for oral suspension USP 250MG/5ML	$195.6K	4

Aurobindo Pharma Usa., Inc, imports 84 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 27 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Amoxicillin	Antibiotics	$24.1M	482	2.4%	4
2	Potassium	Nutritional Supplements	$12.4M	249	1.2%	6
3	Tamoxifen	Advanced Oncology	$4.4M	126	17.2%	1
4	Cefuroxime	Advanced Antibiotics	$3.1M	70	1.4%	7
5	Lenalidomide	Advanced Oncology	$2.5M	51	0.2%	3
6	Cefpodoxime	Advanced Antibiotics	$2.0M	40	0.7%	9
7	Anastrozole	Advanced Oncology	$1.6M	33	1.1%	3
8	Imatinib	Advanced Oncology	$1.6M	32	2.4%	4
9	Methotrexate	Immunosuppressants	$1.2M	25	2.6%	3
10	Capecitabine	Advanced Oncology	$1.1M	23	0.9%	5
11	Vati	Ayurvedic & Herbal Products	$1.0M	20	3.8%	1
12	Alprazolam	CNS & Psychiatric	$948.5K	73	3.1%	7
13	Fluoxetine	CNS & Psychiatric	$850.0K	17	0.4%	15
14	Losartan	Cardiovascular	$850.0K	17	0.3%	10
15	Sertraline	CNS & Psychiatric	$850.0K	17	0.2%	8
16	Exemestane	Advanced Oncology	$750.0K	15	3.1%	2
17	Prednisone	Respiratory	$566.5K	13	2.0%	11
18	Dasatinib	Advanced Oncology	$450.0K	9	1.5%	4
19	Moxifloxacin	Advanced Antibiotics	$442.3K	9	1.3%	6
20	Letrozole	Advanced Oncology	$418.6K	18	1.3%	7
21	Lorazepam	CNS & Psychiatric	$400.0K	8	15.9%	2
22	Minocycline	Advanced Antibiotics	$400.0K	8	0.7%	14
23	Clonazepam	CNS & Psychiatric	$378.9K	13	0.3%	8
24	Spironolactone	Diuretics	$200.0K	4	0.1%	18
25	Sulfamethoxazole	Advanced Antibiotics	$178.5K	5	0.9%	17
26	Torsemide	Diuretics	$100.0K	2	0.5%	11
27	Repaglinide	Advanced Diabetes Medications	$87.7K	3	1.3%	18

Aurobindo Pharma Usa., Inc, imports 27 pharmaceutical products across 11 categories into United States totaling $63.1M. The company is the #1 buyer for 2 products: Tamoxifen, Vati.

Aurobindo Pharma Usa., Inc, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Aurobindo Pharma USA, Inc. (APUSA) is a prominent pharmaceutical importer and distributor based in East Windsor, New Jersey. Established in 2004, APUSA serves as the U.S. sales and marketing arm of Aurobindo Pharma Limited, an Indian multinational pharmaceutical company. The parent company, headquartered in Hyderabad, India, is renowned for manufacturing a diverse range of generic pharmaceuticals and active pharmaceutical ingredients.

APUSA's role in the U.S. pharmaceutical distribution network is multifaceted. It imports finished pharmaceutical formulations from India, focusing on a broad spectrum of therapeutic categories. Leveraging its parent company's state-of-the-art manufacturing facilities, APUSA ensures a consistent supply of quality generic medications to the U.S. market. This vertical integration allows APUSA to maintain control over the entire supply chain, from production to distribution, thereby enhancing efficiency and product availability.

2Distribution Network

APUSA operates a robust distribution network across the United States, with its primary distribution center located in East Windsor, New Jersey. This facility encompasses 567,000 square feet, providing ample space for warehousing and distribution operations. The center is equipped with advanced logistics capabilities, including an Automatic Storage and Retrieval System (ASRS) featuring robotic arms and automated processes for handling inbound and outbound shipments. This technological infrastructure enables APUSA to efficiently manage a vast inventory and fulfill orders promptly.

In addition to its U.S. operations, APUSA's parent company, Aurobindo Pharma Limited, has a global presence with manufacturing facilities across multiple countries. This international footprint facilitates the importation of pharmaceutical products into the U.S., ensuring a steady supply of medications to meet market demands.

3Industry Role

Within the U.S. pharmaceutical supply chain, Aurobindo Pharma USA, Inc. functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from its parent company's manufacturing facilities in India, APUSA plays a crucial role in introducing a wide array of generic medications to the U.S. market. Its operations encompass the importation, warehousing, and distribution of these products, ensuring their availability to various stakeholders, including wholesalers, retailers, and healthcare providers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Aurobindo Pharma Usa., Inc,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

APUSA's sourcing strategy is heavily concentrated, with a significant majority of its imports originating from a single supplier, Aurobindo Pharma Limited. Between 2022 and 2026, APUSA imported approximately $63.1 million worth of pharmaceutical products from India, with 99.6% of these imports sourced from Aurobindo Pharma Limited. This high level of dependency indicates a strategic choice to leverage the parent company's manufacturing capabilities and maintain consistency in product quality and supply. The limited number of suppliers—two in total—suggests a streamlined supply chain but also highlights potential risks associated with supplier concentration.

The stability of this supplier relationship is evidenced by the substantial volume of imports and the consistent number of shipments over the years. However, the minimal engagement with other suppliers, such as Eugia Pharma Specialities Limited, which accounted for only 0.4% of imports, suggests limited diversification in sourcing. This concentration could pose challenges in mitigating risks related to supply chain disruptions, regulatory changes, or geopolitical issues affecting the primary supplier.

2Supply Chain Resilience

Aurobindo Pharma USA, Inc.'s supply chain exhibits a high degree of resilience, primarily due to its vertical integration with Aurobindo Pharma Limited. This integration ensures stringent quality control and adherence to regulatory standards across the manufacturing and distribution processes. The parent company's manufacturing facilities are approved by leading regulatory agencies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO), which underscores their compliance with international quality standards.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet standards for quality, safety, and effectiveness. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines requirements for drug approval, labeling, and manufacturing practices.

For Indian pharmaceutical companies exporting to the U.S., obtaining FDA approval for their drug products is mandatory. This process involves submitting an Abbreviated New Drug Application (ANDA) for generic drugs, which demonstrates that the product is bioequivalent to the reference listed drug. The FDA evaluates these applications to ensure that the imported drugs are safe, effective, and manufactured in compliance with current Good Manufacturing Practices (cGMP).

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. All foreign drug establishments whose products are imported must register with the FDA and list all their drug products intended for commercial distribution in the United States. This registration ensures that the FDA is notified of all regulated products imported into the country.

Aurobindo Pharma Usa., Inc, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Aurobindo Pharma USA, Inc. focuses on importing a diverse range of generic pharmaceutical products across various therapeutic categories. Between 2022 and 2026, APUSA imported 27 products spanning 11 therapeutic areas, with the top three categories being Antibiotics (38.2%), Advanced Oncology (20.6%), and Nutritional Supplements (19.7%).

This strategic focus aligns with market demand for affordable and

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Aurobindo Pharma Usa., Inc,

What products does Aurobindo Pharma Usa., Inc, import from India?

Aurobindo Pharma Usa., Inc, imports 27 pharmaceutical products across 11 categories. Top imports: Amoxicillin ($24.1M), Potassium ($12.4M), Tamoxifen ($4.4M), Cefuroxime ($3.1M), Lenalidomide ($2.5M).

Who supplies pharmaceuticals to Aurobindo Pharma Usa., Inc, from India?

Aurobindo Pharma Usa., Inc, sources from 2 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (99.6% of imports, $11.3M).

What is Aurobindo Pharma Usa., Inc,'s total pharmaceutical import value?

Aurobindo Pharma Usa., Inc,'s total pharmaceutical import value from India is $63.1M, based on 1,382 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Aurobindo Pharma Usa., Inc, focus on?

Aurobindo Pharma Usa., Inc, imports across 11 categories. The largest: Antibiotics (38.2%), Advanced Oncology (20.6%), Nutritional Supplements (19.7%).

Get Full Aurobindo Pharma Usa., Inc, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 7 company name variants from customs records. For current shipment-level data, contact TransData Nexus.